Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300027 | 0.90 | PTGDR2 (0.61) | PTGDR2TSHRSMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL2769602 | 0.88 | PTGDR2 (0.58) | PTGDR2APEX1LMNAGAA | |
| SCHEMBL3570494 | 0.86 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL2769552 | 0.79 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL2771887 | 0.78 | PTGDR2 (0.47) | PTGDR2TSHRSMN1; SMN2ALDH1A1USP2 | |
| SCHEMBL3573695 | 0.76 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL3572270 | 0.76 | PTGDR2 (0.80) | PTGDR2ALDH1A1GAAKMT2A | |
| SCHEMBL3569319 | 0.75 | PTGDR2 (0.65) | PTGDR2TSHRLMNA | |
| SCHEMBL2770201 | 0.74 | PTGDR2 (0.75) | PTGDR2TSHRTDP1 | |
| SCHEMBL2768653 | 0.73 | PTGDR2 (0.46) | PTGDR2TSHRSMN1; SMN2ALDH1A1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121686-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | HRH2, HRH4, HRH1 | PTGDR2 168/4885TSHR 6/4885SMN1; SMN2 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.